A pharmacological treatment algorithm for localized neuropathic pain

References

• Treede RD, Jensen TS, Campbell JN, et al. Redefinition of neuropathic pain and a grading system for clinical use: consensus statement on clinical and research diagnostic criteria. Neurology 2008;70:1630-5
   PubMed Web of Science ®Google Scholar
• Hansson P. Neuropathic pain: clinical characteristics and diagnostic workup. Eur J Pain 2002;6(Suppl A):47-50
   PubMed Web of Science ®Google Scholar
• Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807-19
   PubMed Web of Science ®Google Scholar
• Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7:281-9
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Lantéri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380-7
   PubMed Web of Science ®Google Scholar
• Langley PC, Van Litsenburg C, Cappelleri JC, Carroll D. The burden associated with neuropathic pain in Western Europe. J Med Econ 2013;16:85-95
   PubMedGoogle Scholar
• Dworkin R, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73
   PubMed Web of Science ®Google Scholar
• Mick G, Baron R, Finnerup NB, et al. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manage 2012;2:71-7
   PubMedGoogle Scholar
• Mick G, Baron R, Correa-Illanes G, et al. Is an easy and reliable diagnosis of localized neuropathic pain (LNP) possible in general practice? Development of a screening tool based on IASP criteria. Curr Med Res Opin 2014;30:1357-66
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-23
   PubMed Web of Science ®Google Scholar
• Moore RA, Wiffen PJ, Eccleston C, et al. Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting. Pain 2015;156:1382-95
   PubMed Web of Science ®Google Scholar
• Arning K, Baron R. Evaluation of symptom heterogeneity in neuropathic pain using assessments of sensory functions. Neurotherapeutics 2009;738-48
   PubMed Web of Science ®Google Scholar
• Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy. Clin Drug Invest 2009;29:231-41
   PubMed Web of Science ®Google Scholar
• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
   PubMed Web of Science ®Google Scholar
• Flores MP, Castro APCR, Nascimento JS. Topical analgesics. Rev Bras Anestesiol 2012;62:244-52
   PubMed Web of Science ®Google Scholar
• Navez ML, Monella C, Bösl I, et al. 5% Lidocaine medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability. Pain Ther 2015;4:1-15
   PubMed Web of Science ®Google Scholar
• Stanos SP, Galluzzi KE. Topical therapies in the management of chronic pain. Postgrad Med 2013;125(4 Suppl 1):25-33
   PubMedGoogle Scholar
• Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44
   PubMed Web of Science ®Google Scholar
• Comer AM, Lamb HM. Lidocaine patch 5%. Drugs 2000;59:245-9
   PubMed Web of Science ®Google Scholar
• Overholser BR, Foster DR. Opioid pharmacokinetic drug–drug interactions. Am J Manag Care 2011;17(Suppl 11):S276-87
   PubMedGoogle Scholar
• Brennan MJ. The clinical implications of cytochrome p450 interactions with opioids and strategies for pain management. J Pain Symptom Manage 2012;44(6 Suppl):S15-22
   Google Scholar
• Chianta M, Guevara M. Pharmacogenetics and pain management: an opportunity to advance personalized patient care. Medical Laboratory Observer 2014. Available at: http://www.mlo-online.com/articles/201402/pharmacogenetics-and-pain-management-an-opportunity-to-advance-personalized-patient-care.php [Last accessed 22 September 2015]
   Google Scholar
• Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manag 2004;28:396-410
   PubMed Web of Science ®Google Scholar
• Jorge LL, Feres CC, Teles VEP. Topical preparations for pain relief: efficacy and patient adherence. J Pain Res 2011;4:11-24
   Google Scholar
• Hernández-Puiggròs P, Pélaez R, Morell A, et al. Analysis of the efficacy of the lidocaine patch 5% in the treatment of neuropathic pain: our feedback. Pain Studies Treatment 2014;2:91-8
   Google Scholar
• Mick G, Correa-Illanes C. Topical pain management with the 5% lidocaine medicated plaster – a review. Curr Med Res Opin 2012;28:937-51
   PubMed Web of Science ®Google Scholar
• Casale R, Di Matteo M, Minella CE, et al. Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster: a case series. J Pain Res 2014;7:353-7
   PubMed Web of Science ®Google Scholar
• Correa-Illanes G, Roa R, Piñeros JL, Calderón W. Use of 5% lidocaine medicated plaster to treat localized neuropathic pain secondary to traumatic injury of peripheral nerves. Local Reg Anesth 2012;5:47-53
   PubMedGoogle Scholar
• Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533-8
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia. Drugs 2009;69:2149-65
   PubMed Web of Science ®Google Scholar
• Groninger H, Schisler RE. Topical capsaicin for neuropathic pain. J Palliat Med 2012;15:946-7
   PubMed Web of Science ®Google Scholar
• Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011;107:490-502
   PubMed Web of Science ®Google Scholar
• Qutenza Prescribing Information. Available at: www.qutenza.com/_docs/Qutenza%20Treatment%20Guide.pdf [Last accessed 7 July 2015]
   Google Scholar
• Mou J, Paillard F, Turnbull B, et al. Efficacy of Qutenza (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza clinical trials database. Pain 2013;154:1632-9
   PubMed Web of Science ®Google Scholar
• Wagner T, Poole C, Roth-Daniek A. The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis. Pain Med 2013;14:1202-11
   PubMed Web of Science ®Google Scholar
• Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2012;9:CD010111
   PubMed Web of Science ®Google Scholar
• Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 2012;153:1815-23
   PubMed Web of Science ®Google Scholar
• Kiani J, Sadeji F, Nasrollahi SA, Esna-Ashari F. A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. J Res Med Sci 2015;20:359-63
   PubMed Web of Science ®Google Scholar
• Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain 2002;18(6 Suppl):S125-32
   PubMed Web of Science ®Google Scholar
• Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008;64:274-8
   PubMed Web of Science ®Google Scholar
• Colhado OC, Boeing M, Ortega LB. Botulinum toxin in pain treatment. Rev Bras Anestesiol 2009;59:366-81
   PubMedGoogle Scholar
• Sim WS. Application of botulinum toxin in pain management. Korean J Pain 2011;24:1-6
   PubMedGoogle Scholar
• Apalla Z, Sotiriou E, Lallas A, et al. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain 2013;29:857-64
   PubMed Web of Science ®Google Scholar
• Agrawal RP, Goswami J, Jain S, Kochar DK. Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective double-blind randomized placebo-controlled study. Diabetes Res Clin Pract 2009;83:371-8
   PubMed Web of Science ®Google Scholar
• Kim JY, Lim HJ, Lee WJ, et al. Efficacy of piroxicam patch compared to lidocaine patch for the treatment of postherpetic neuralgia. Ann Dermatol 2011;23:162-9
   PubMed Web of Science ®Google Scholar